Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ardelyx Bets Big On Tenapanor’s Potential, Despite Side Effect Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

Unwinding NHE3 partnership with AstraZeneca, Ardelyx plans to move first-in-class agent into Phase III in IBS-C while seeking more tolerable dosing regimen for late-stage development in hyperphosphatasia.

Advertisement

Related Content

Deals Of The Week: AstraZeneca/Ardelyx, Roche/Inception, GlaxoSmithKline/Aeras

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078641

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel